Data-driven unbiased curation of the TP53 tumor suppressor gene mutation database and validation by ultradeep sequencing of human tumors

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 24, 2012, Pages 9551-9556

  Edlund, Karolina ^a   Larsson, Ola ^b   Ameur, Adam ^a   Bunikis, Ignas ^a   Gyllensten, Ulf ^a   Leroy, Bernard ^c   Sundström, Magnus ^a   Micke, Patrick ^a   Botling, Johan ^a   Soussi, Thierry ^b,c  

^a UPPSALA UNIVERSITY   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c SORBONNE UNIVERSITÉ   (France)

Author keywords

Cancer genetics; Genomic; Locus specific database

Indexed keywords

PROTEIN P53;

ACCURACY; ARTICLE; BREAST CANCER; CANCER GENETICS; CODON; COLORECTAL CANCER; CONTROLLED STUDY; DOUBLE STRANDED DNA BREAK; EXON; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; GENETIC DATABASE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; ULTRADEEP SEQUENCING;

DATABASES, GENETIC; GENES, P53; GENES, TUMOR SUPPRESSOR; HUMANS; MUTATION; NEOPLASMS;

EID: 84862203277     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1200019109     Document Type: Article

References (33)

1. Bamford S, et al. (2004) The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br J Cancer 91:355-358. (Pubitemid 39037083)
2. Forbes SA, et al. (2011) COSMIC: Mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res 39(Database issue):D945-D950.
3. Meyerson M, Gabriel S, Getz G (2010) Advances in understanding cancer genomes through second-generation sequencing. Nat Rev Genet 11:685-696.
4. Chanock SJ, Thomas G (2007) The devil is in the DNA. Nat Genet 39:283-284. (Pubitemid 46328477)
5. Soussi T (2011) Advances in carcinogenesis: A historical perspective from observational studies to tumor genome sequencing and TP53 mutation spectrum analysis. Biochim Biophys Acta 1816:199-208.
6. Vousden KH, Lane DP (2007) p53 in health and disease. Nat Rev Mol Cell Biol 8: 275-283. (Pubitemid 46474662)
7. Robles AI, Harris CC (2010) Clinical outcomes and correlates of TP53 mutations and cancer. Cold Spring Harb Perspect Biol 2:a001016.
8. Joerger AC, Fersht AR (2010) The tumor suppressor p53: From structures to drug discovery. Cold Spring Harb Perspect Biol 2:a000919.
9. Caron de Fromentel C, Soussi T (1992) TP53 tumor suppressor gene: A model for investigating human mutagenesis. Genes Chromosomes Cancer 4:1-15.
10. Hollstein M, Sidransky D, Vogelstein B, Harris CC (1991) p53 mutations in human cancers. Science 253:49-53. (Pubitemid 21917115)
11. Soussi T (2011) TP53 mutations in human cancer: Database reassessment and prospects for the next decade. Adv Cancer Res 110:107-139.
12. Soussi T, Ishioka C, Claustres M, Béroud C (2006) Locus-specific mutation databases: Pitfalls and good practice based on the p53 experience. Nat Rev Cancer 6:83-90. (Pubitemid 43053654)
13. Soussi T, et al. (2006)Meta-analysis of the p53mutation database for mutant p53 biological activity reveals a methodologic bias in mutation detection. Clin Cancer Res 12:62-69. (Pubitemid 43166177)
14. Olivier M, Hollstein M, Hainaut P (2010) TP53 mutations in human cancers: Origins, consequences, and clinical use. Cold Spring Harb Perspect Biol 2:a001008.
15. Patocs A, et al. (2007) Breast-cancer stromal cells with TP53 mutations and nodal metastases. N Engl J Med 357:2543-2551. (Pubitemid 350294221)
16. Holstege H, et al. (2009) High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer. Cancer Res 69:3625-3633.
17. Kato S, et al. (2003) Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci USA 100:8424-8429. (Pubitemid 36842561)
18. Soussi T, Kato S, Levy PP, Ishioka C (2005) Reassessment of the TP53 mutation database in human disease by data mining with a library of TP53 missense mutations. Hum Mutat 25:6-17. (Pubitemid 40075908)
19. Resnick MA, Inga A (2003) Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity. Proc Natl Acad Sci USA 100: 9934-9939. (Pubitemid 37087046)
20. Berglind H, Pawitan Y, Kato S, Ishioka C, Soussi T (2008) Analysis of p53 mutation status in human cancer cell lines: A paradigm for cell line cross-contamination. Cancer Biol Ther 7:699-708.
21. Joerger AC, Fersht AR (2007) Structure-function-rescue: The diverse nature of common p53 cancer mutants. Oncogene 26:2226-2242. (Pubitemid 46536643)
22. Hamroun D, et al. (2006) The UMD TP53 database and website: Update and revisions. Hum Mutat 27:14-20. (Pubitemid 43042962)
23. Greenman C, et al. (2007) Patterns of somatic mutation in human cancer genomes. Nature 446:153-158. (Pubitemid 46398669)
24. Williams C, et al. (1999) A high frequency of sequence alterations is due to formalin fixation of archival specimens. Am J Pathol 155:1467-1471.
25. Akbari M, Hansen MD, Halgunset J, Skorpen F, Krokan HE (2005) Low copy number DNA template can render polymerase chain reaction error prone in a sequence-dependent manner. J Mol Diagn 7:36-39. (Pubitemid 40310163)
26. Zander CS, Soussi T (2008) Breast-cancer stromal cells with TP53 mutations. N Engl J Med 358:1635-author reply 1636.
27. Campbell IG, Qiu W, Polyak K, Haviv I (2008) Breast-cancer stromal cells with TP53 mutations. N Engl J Med 358:1634-1635, author reply 1636.
28. Qiu W, et al. (2008) No evidence of clonal somatic genetic alterations in cancer-associated fibroblasts from human breast and ovarian carcinomas. Nat Genet 40: 650-655. (Pubitemid 351601206)
29. Gallegos Ruiz MI, et al. (2007) EGFR and K-ras mutation analysis in non-small cell lung cancer: Comparison of paraffin embedded versus frozen specimens. Cell Oncol 29: 257-264. (Pubitemid 46855706)
30. Marchetti A, Felicioni L, Buttitta F (2006) Assessing EGFR mutations. N Engl J Med 354: 526-528, author reply 526-528.
31. Lamy A, et al. (2011) Metastatic colorectal cancer KRAS genotyping in routine practice: Results and pitfalls. Mod Pathol 24:1090-1100.
32. Kern SE, Winter JM (2006) Elegance, silence and nonsense in the mutations literature for solid tumors. Cancer Biol Ther 5:349-359.
33. Winter JM, Brody JR, Kern SE (2006) Multiple-criterion evaluation of reported mutations: A proposed scoring system for the intragenic somatic mutation literature. Cancer Biol Ther 5:360-370.